Related Experiment Video
Updated: Feb 19, 2026
08:32
Development and Assessment of Intracellular Infection Models for Staphylococcus aureus
Published on: January 17, 2025
1.3K
Pharmacotherapeutic options for treating Staphylococcus aureus bacteremia
Carlota Gudiol1,2,3, Guillermo Cuervo1,3, Evelyn Shaw1,3
1a Infectious Diseases Department , Bellvitge University Hospital, IDIBELL. L'Hospitalet de Llobregat , Barcelona , Spain.
Expert Opinion on Pharmacotherapy
|November 9, 2017
Summary
Staphylococcus aureus bacteremia (SAB) treatment remains challenging, with high fatality rates. New antibiotics offer hope, but more clinical data is needed to optimize their use in treating SAB.
Area of Science:
- Infectious Diseases
- Pharmacology
- Internal Medicine
Background:
- Staphylococcus aureus bacteremia (SAB) has persistently high case-fatality rates, with limited improvement over decades.
- Treating SAB, particularly methicillin-resistant strains, presents ongoing clinical challenges.
- Emerging anti-staphylococcal antibiotics are being explored as alternatives to conventional therapies.
Purpose of the Study:
- To provide an updated review of current antibiotic options for SAB treatment.
- To detail pharmacological properties, indications, and adverse events of existing and novel anti-staphylococcal agents.
- To summarize existing evidence on the efficacy of these agents in treating SAB.
Main Methods:
- Literature review of current antibiotics for Staphylococcus aureus bacteremia.
- Analysis of pharmacological characteristics, indications, and adverse events.
- Evaluation of clinical evidence for antibiotic use in SAB.
Main Results:
- The review covers established and new anti-staphylococcal antibiotics.
- Information on drug properties, approved uses, and side effects is presented.
- Evidence supporting the use of these agents in SAB treatment is discussed.
Conclusions:
- SAB patient management requires a multidisciplinary approach.
- New treatment options exist for methicillin-resistant SAB.
- Further clinical trials are essential to define optimal roles for new antibiotics and combination therapies in SAB management.
Related Concept Videos
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
477
Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
477
01:28Pneumonia IV: Management
839
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
839
01:27Combined Effects of Drugs: Synergism
7.0K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
7.0K
01:26Mitral Stenosis III: Medical Management
322
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
322
01:18Endocarditis III: Medical Management
269
Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
269
01:29Inflammatory Bowel Disease IV: Pharmacological Management
817
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
817